Daré Bioscience, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
September 07 2017 - 8:30AM
Daré Bioscience, Inc. (NASDAQ:DARE), a healthcare company committed
to the development and commercialization of innovative products in
women’s reproductive health, today announced that Sabrina Martucci
Johnson, Chief Executive Officer and Founder, will present at the
19th Annual Rodman & Renshaw Global Investment Conference on
Monday, September 11, 2017 at 12:30 p.m. Eastern Time in New York,
NY. Ms. Johnson will provide a Daré overview and business update.
The presentation will be webcast live and may be accessed by
visiting Daré’s website at http://ir.darebioscience.com. A replay
of the webcast will be available for 10 business days.
About Daré Bioscience
Daré Bioscience is a healthcare company committed to the
development and commercialization of innovative products in women's
reproductive health. Daré believes there is an unmet global need in
women's reproductive health for new products that expand options,
improve outcomes and are easy to use. Product development in
women’s reproductive health is fragmented creating a potential
opportunity for Daré. The Company seeks to fill this gap by
taking promising product candidates through clinical development
and believes the team is well suited to ensure current and
potential future product candidates advance and one day become
commercially available to women worldwide. Daré's executive
management team brings experience in global women's healthcare as
well as a track record of success in prior ventures in financing,
partnering, commercializing, and achieving regulatory approval for
medical devices, therapeutics and diagnostics. For more information
on Daré, please visit www.darebioscience.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within
the meaning of The Private Securities Litigation Reform Act of 1995
regarding matters that are not historical facts, including
statements relating to Daré's expectations regarding the
anticipated market demands for its products, the safety and
effectiveness of its products, market acceptance of Dare’s products
and the qualifications and expertise of Dare’s management team.
Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or
implied by such forward-looking statements as a result of various
important factors, including the uncertainties inherent in the
initiation and completion of clinical trials; availability and
timing of data from ongoing and future clinical trials and the
results of such trials; whether preliminary results from a clinical
trial will be predictive of the final results of that trial or
whether results of early clinical trials will be indicative of the
results of later clinical trials, expectations for regulatory
approvals; claims of infringement and other risks relating to
Daré's owned and licensed intellectual property rights, and other
factors discussed in the "Risk Factors" section of Daré's Quarterly
Report on Form 10-Q filed with the SEC on August 14, 2017. In
addition, any forward-looking statements included in this press
release represent our views only as of the date of this release and
should not be relied upon as representing our views as of any
subsequent date. Daré specifically disclaims any obligation to
update any forward-looking statements included in this press
release.
CONTACT:
innovations@darebioscience.comPhone:
858-926-7655
Source: Daré Bioscience
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dare Bioscience (NASDAQ:DARE)
Historical Stock Chart
From Sep 2023 to Sep 2024